Kymera (NASDAQ: KYMR) CBO exercises options and sells 2,500 shares at $99

Rhea-AI Filing Summary

Kymera Therapeutics Chief Business Officer Noah Goodman exercised stock options for 2,500 shares of common stock at $21.05 per share and on the same day sold 2,500 shares in an open-market transaction at $99.00 per share. Following these transactions, he directly holds 50,195.438 shares of common stock. The trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares ($247,500)

Net Sell 3 txns

Insider Goodman Noah

Role Chief Business Officer

Sold 2,500 shs ($248K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,500	$0.00	--
Exercise	Common Stock	2,500	$21.05	$53K
Sale	Common Stock	2,500	$99.00	$248K

Holdings After Transaction: Stock Option (Right to Buy) — 95,000 shares (Direct, null); Common Stock — 52,695.438 shares (Direct, null)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

Key Figures

Shares sold: 2,500 shares Sale price: $99.00 per share Options exercised: 2,500 shares +3 more

6 metrics

Shares sold 2,500 shares Open-market sale of common stock

Sale price $99.00 per share Price for 2,500 common shares sold

Options exercised 2,500 shares Stock option converted into common stock

Exercise price $21.05 per share Stock option exercise price

Shares held after 50,195.438 shares Direct common stock ownership after transactions

Option expiration 2035-04-07 Expiration date of stock option exercised

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), open-market sale, exercise or conversion of derivative security

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 05:47 PM Accepted by SEC EDGAR 06/22/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodman Noah

(Last) (First) (Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		M(1)		2,500	A	$21.05	52,695.438	D
Common Stock	06/22/2026		S(1)		2,500	D	$99	50,195.438	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.05	06/22/2026		M(1)			2,500	(2)	04/07/2035	Common Stock	2,500	$0	95,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.

2. Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Kymera Therapeutics (KYMR) report for Noah Goodman?

Kymera Therapeutics reported that Chief Business Officer Noah Goodman exercised options for 2,500 shares and sold 2,500 shares of common stock. These transactions occurred on the same date and were disclosed in a Form 4 insider trading report filed with regulators.

At what prices did Noah Goodman trade Kymera Therapeutics (KYMR) shares?

Noah Goodman exercised stock options at an exercise price of $21.05 per share and sold 2,500 Kymera Therapeutics common shares at $99.00 per share. This reflects a significant spread between his option strike price and the open-market sale price realized.

How many Kymera Therapeutics (KYMR) shares does Noah Goodman hold after these trades?

After the reported transactions, Noah Goodman directly holds 50,195.438 shares of Kymera Therapeutics common stock. This post-transaction ownership figure comes from the Form 4 and helps investors gauge the scale of his remaining equity stake relative to the shares sold.

Were Noah Goodman’s Kymera Therapeutics (KYMR) trades under a Rule 10b5-1 plan?

Yes. The footnotes state that these transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Such plans are pre-arranged, allowing executives to sell shares according to a preset schedule rather than discretionary market timing.

What type of derivative security did Noah Goodman exercise at Kymera Therapeutics (KYMR)?

Noah Goodman exercised a stock option covering 2,500 shares of Kymera Therapeutics common stock with a conversion or exercise price of $21.05 per share. This option was described as a "Stock Option (Right to Buy)" with an expiration date in 2035.